Nothing Special   »   [go: up one dir, main page]

SG10201806917PA - Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics - Google Patents

Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics

Info

Publication number
SG10201806917PA
SG10201806917PA SG10201806917PA SG10201806917PA SG10201806917PA SG 10201806917P A SG10201806917P A SG 10201806917PA SG 10201806917P A SG10201806917P A SG 10201806917PA SG 10201806917P A SG10201806917P A SG 10201806917PA SG 10201806917P A SG10201806917P A SG 10201806917PA
Authority
SG
Singapore
Prior art keywords
drug
ligand
linkers
pegylated
targeted cells
Prior art date
Application number
SG10201806917PA
Inventor
Robert Lyon
Patrick Burke
Joshua Hunter
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52828847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201806917P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of SG10201806917PA publication Critical patent/SG10201806917PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A61K47/6885—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy the conjugate or the polymer being a starburst, a dendrimer, a cascade
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS The present invention provides Ligand-Drug Conjugates comprising a PEG Unit in a parallel orientation to the Drug Unit. The invention provides inter alia, Ligand- Drug Conjugates (LDCs), methods of preparing and using them, and intermediates thereof. The Ligand- Drug Conjugates are stable in circulation, yet capable of inflicting cell death on targeted cells or inhibiting proliferation of targeted cells once its drug cargo is released in the vicinity or within targeted cells. In principle embodiments, an LDC of the present invention is represented by the structure of Formula I. [Figure 1]
SG10201806917PA 2013-10-15 2014-10-14 Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics SG10201806917PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361891320P 2013-10-15 2013-10-15
US201461941904P 2014-02-19 2014-02-19
US201461947742P 2014-03-04 2014-03-04
US201461975318P 2014-04-04 2014-04-04

Publications (1)

Publication Number Publication Date
SG10201806917PA true SG10201806917PA (en) 2018-09-27

Family

ID=52828847

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201806917PA SG10201806917PA (en) 2013-10-15 2014-10-14 Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
SG10201707274WA SG10201707274WA (en) 2013-10-15 2014-10-14 Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
SG11201600954XA SG11201600954XA (en) 2013-10-15 2014-10-14 Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201707274WA SG10201707274WA (en) 2013-10-15 2014-10-14 Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
SG11201600954XA SG11201600954XA (en) 2013-10-15 2014-10-14 Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics

Country Status (23)

Country Link
US (3) US11103593B2 (en)
EP (2) EP3756663A1 (en)
JP (4) JP6747971B2 (en)
KR (4) KR20240034882A (en)
CN (1) CN105764503A (en)
AU (3) AU2014337555C1 (en)
BR (1) BR112016007622A2 (en)
CA (2) CA3187392A1 (en)
CY (1) CY1123675T1 (en)
DK (1) DK3057585T3 (en)
EA (1) EA201690780A1 (en)
ES (1) ES2826398T3 (en)
HU (1) HUE051389T2 (en)
IL (4) IL293071A (en)
MX (4) MX2021008464A (en)
NZ (2) NZ758050A (en)
PL (1) PL3057585T3 (en)
PT (1) PT3057585T (en)
SG (3) SG10201806917PA (en)
SI (1) SI3057585T1 (en)
TW (4) TW202417050A (en)
WO (1) WO2015057699A2 (en)
ZA (1) ZA201601436B (en)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201806917PA (en) 2013-10-15 2018-09-27 Seattle Genetics Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
KR101628872B1 (en) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 Compounds comprising self-immolative group
EP3218009B1 (en) * 2014-10-14 2021-04-07 Polytherics Limited Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
ES2960741T3 (en) * 2014-10-24 2024-03-06 Abzena Uk Ltd Conjugates and conjugation reagents
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
EP3662933A1 (en) * 2015-03-18 2020-06-10 Seattle Genetics, Inc. Cd48 antibodies and conjugates thereof
JP6486316B2 (en) 2015-11-03 2019-03-20 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Antibody-drug conjugate (ADC) and method for forming the same
US11173214B2 (en) 2015-11-25 2021-11-16 Legochem Biosciences, Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
KR20180077300A (en) * 2015-11-25 2018-07-06 주식회사 레고켐 바이오사이언스 Joints comprising peptide groups and related manufacturing methods
KR20180079452A (en) 2015-11-25 2018-07-10 주식회사 레고켐 바이오사이언스 Conjugates comprising self-sacrificial groups and methods for their preparation
TWI852735B (en) * 2015-12-04 2024-08-11 美商思進公司 Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
WO2017161206A1 (en) * 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
WO2017165851A1 (en) * 2016-03-25 2017-09-28 Seattle Genetics, Inc. Process for the preparation of pegylated drug-linkers and intermediates thereof
MA45328A (en) 2016-04-01 2019-02-06 Avidity Biosciences Llc NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
WO2017178828A1 (en) * 2016-04-14 2017-10-19 Polytherics Limited Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring
EP3454909A1 (en) 2016-05-10 2019-03-20 Bristol-Myers Squibb Company Antibody-drug conjugates of tubulysin analogs with enhanced stability
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP7031934B2 (en) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ Separation matrix
US11708390B2 (en) 2016-05-11 2023-07-25 Cytiva Bioprocess R&D Ab Method of storing a separation matrix
JP6987424B2 (en) 2016-05-11 2022-01-05 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ How to clean and / or disinfect the isolation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
EP3455243B1 (en) 2016-05-11 2021-03-24 Cytiva BioProcess R&D AB Separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
TWI851531B (en) 2016-08-09 2024-08-11 美商思進公司 Drug conjugates with self-stabilizing linkers having improved physiochemical properties
DK3525826T3 (en) 2016-10-11 2020-08-24 Byondis Bv Non-linear self-sacrificing linkers and their conjugates
EP3529269A2 (en) 2016-10-19 2019-08-28 Invenra, Inc. Antibody constructs
IL307357A (en) 2016-11-08 2023-11-01 Regeneron Pharma Steroids and protein-conjugates thereof
US11628225B2 (en) 2016-11-14 2023-04-18 CHO Pharma Inc. Antibody-drug conjugates
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
JP7244987B2 (en) * 2016-12-14 2023-03-23 シージェン インコーポレイテッド Multidrug Antibody Drug Conjugates
EP3559039A1 (en) 2016-12-22 2019-10-30 Università Degli Studi Magna Graecia Catanzaro A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
WO2018128826A1 (en) * 2017-01-06 2018-07-12 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections
CN110381980A (en) 2017-01-06 2019-10-25 艾维迪提生物科学有限责任公司 The method that nucleic acid-peptide composition and inducing exon are skipped
EP3600443A1 (en) 2017-03-24 2020-02-05 Seattle Genetics, Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
CA3058360A1 (en) 2017-03-29 2018-10-04 Legochem Biosciences, Inc. Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same
WO2018181059A1 (en) 2017-03-30 2018-10-04 日油株式会社 Heterobifunctional monodispersed polyethylene glycol, and complex using same
US11931414B2 (en) 2017-04-27 2024-03-19 Seagen Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
KR102722886B1 (en) 2017-05-10 2024-10-29 사노피 Novel peptide linkers and cryptophycin conjugates, their preparation and therapeutic uses
US11491237B2 (en) 2017-05-18 2022-11-08 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
KR20200010491A (en) * 2017-05-23 2020-01-30 신톤 바이오파머슈티칼즈 비.브이. Double Conjugation Method for Preparing Antibody-Drug Conjugates
CN113952469A (en) 2017-06-19 2022-01-21 四川百利药业有限责任公司 Antibody-drug conjugate with acidic self-stabilizing joint
CA3067829A1 (en) 2017-06-23 2018-12-27 VelosBio Inc. Ror1 antibody immunoconjugates
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. Compounds compositions, and methods for the treatment of disease
US11707531B2 (en) 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
CA3126646A1 (en) 2017-09-29 2019-04-04 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
CN118267396A (en) 2017-10-04 2024-07-02 艾维迪提生物科学公司 Nucleic acid-polypeptide compositions and uses thereof
US20200345863A1 (en) 2017-10-23 2020-11-05 Mablink Bioscience Ligand-drug-conjugate comprising a single molecular weight polysarcosine
IL313068A (en) * 2017-11-07 2024-07-01 Regeneron Pharma Hydrophilic linkers for antibody drug conjugates
CN111655294A (en) * 2017-11-14 2020-09-11 德比欧药物研究有限公司 Ligand-drug-conjugates as substrates for selective cleavage by cathepsin B peptidase activity
KR20200090195A (en) * 2017-11-22 2020-07-28 시애틀 지네틱스, 인크. Acid-mediated assay for analysis of ligand-drug conjugates
EP3717021A1 (en) 2017-11-27 2020-10-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
WO2019113393A1 (en) 2017-12-06 2019-06-13 Avidity Biosciences Llc Compositions and methods of treating muscle atrophy and myotonic dystrophy
JP2021506883A (en) 2017-12-21 2021-02-22 メルサナ セラピューティクス インコーポレイテッド Pyrrolobenzodiazepine antibody conjugate
MX2020006994A (en) 2018-01-08 2020-11-06 Regeneron Pharma Steroids and antibody-conjugates thereof.
KR102542988B1 (en) 2018-03-13 2023-06-13 니치유 가부시키가이샤 Heterobifunctional compound having monodisperse polyethylene glycol in main chain and side chain
EP3768714A1 (en) 2018-03-23 2021-01-27 Seagen Inc. Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
CN112601555A (en) 2018-05-09 2021-04-02 乐高化学生物科学股份有限公司 Compositions and methods relating to anti-CD 19 antibody drug conjugates
WO2019217591A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
US20210246187A1 (en) 2018-06-05 2021-08-12 King's College London Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
TWI851577B (en) * 2018-06-07 2024-08-11 美商思進公司 Camptothecin conjugates
JP2022513400A (en) * 2018-10-29 2022-02-07 メルサナ セラピューティクス インコーポレイテッド Cysteine-manipulated antibody with peptide-containing linker-drug conjugate
WO2020123882A1 (en) * 2018-12-12 2020-06-18 The General Hospital Corporation Prodrugs with a tridentate self-immolative linker
MX2021007548A (en) * 2018-12-21 2021-12-10 Seagen Inc Adcs with thiol multiplex linkers.
IL297818B2 (en) 2018-12-21 2024-09-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and uses thereof
EA202192555A1 (en) 2019-03-19 2021-11-25 Фундасио Привада Институт Д'Инвестигасио Онколохика Де Валь Эброн COMBINATION THERAPY FOR CANCER TREATMENT
WO2020236521A1 (en) * 2019-05-17 2020-11-26 The Regents Of The University Of California Traceless linker and methods of use thereof
WO2020236841A2 (en) 2019-05-20 2020-11-26 Novartis Ag Antibody drug conjugates having linkers comprising hydrophilic groups
CA3142283A1 (en) 2019-06-06 2020-12-10 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
WO2020247818A1 (en) 2019-06-06 2020-12-10 Avidity Biosciences, Inc. Una amidites and uses thereof
KR20210028544A (en) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 Antibody-drug conjugate comprising antibody binding to antibody against human ROR1 and its use
JP2022548306A (en) 2019-09-19 2022-11-17 シージェン インコーポレイテッド Selective drug release from conjugates of internalized biologically active compounds
EP4037717A1 (en) 2019-10-04 2022-08-10 Seagen Inc. Camptothecin peptide conjugates
US11786605B2 (en) 2020-01-09 2023-10-17 Mersana Therapeutics, Inc. Site specific antibody-drug conjugates with peptide-containing linkers
EP4096717A1 (en) 2020-01-31 2022-12-07 Innate Pharma Treatment of cancer
CN115666589A (en) 2020-03-19 2023-01-31 艾维迪提生物科学公司 Compositions and methods for treating facioscapulohumeral muscular dystrophy
CA3177180A1 (en) 2020-03-27 2021-09-30 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy
IL296901A (en) 2020-04-02 2022-12-01 Mersana Therapeutics Inc Antibody drug conjugates comprising sting agonists
US20230173093A1 (en) 2020-04-10 2023-06-08 Seagen Inc. Charge variant linkers
EP4117729A4 (en) * 2020-04-15 2023-11-15 Shenzhen Enduring Biotech, Ltd. Antibody-drug conjugate
JP2023526236A (en) * 2020-05-13 2023-06-21 シージェン インコーポレイテッド Methods of treating cancer using anti-CD30 antibody-drug conjugate combinations
CN113941007B (en) * 2020-07-16 2024-06-07 成都科岭源医药技术有限公司 Tandem double-drug linked assembly unit and application thereof
KR20230104659A (en) 2020-11-08 2023-07-10 씨젠 인크. Combination-Therapy Antibody Drug Conjugates Using Immune Cell Inhibitors
EP4251207A1 (en) 2020-11-25 2023-10-04 Innate Pharma Treatment of cancer
EP4267193A1 (en) 2020-12-23 2023-11-01 Ludwig-Maximilians-Universität München Improved cd30 targeting antibody drug conjugates and uses thereof
EP4277904A1 (en) 2021-01-15 2023-11-22 Seagen Inc. Immunomodulatory antibody-drug conjugates
US11510994B2 (en) * 2021-01-29 2022-11-29 EqIP, LLC Linkers for improving the stability of bioconjugates and the selectivity of payload release
JP2024506300A (en) 2021-02-03 2024-02-13 シージェン インコーポレイテッド Immune stimulating compounds and conjugates
JP2024507275A (en) * 2021-02-23 2024-02-16 ザ チルドレンズ メディカル センター コーポレーション Intercellular adhesion molecule 1 (ICAM1) antibody drug conjugates and their uses
TW202300179A (en) 2021-03-18 2023-01-01 美商西根公司 Selective drug release from internalized conjugates of biologically active compounds
WO2022198231A1 (en) 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
CA3212610A1 (en) * 2021-04-20 2022-10-27 Philip MOQUIST Modulation of antibody-dependent cellular cytotoxicity
CA3221398A1 (en) 2021-05-28 2022-12-01 Seagen Inc. Anthracycline antibody conjugates
WO2022255425A1 (en) 2021-06-01 2022-12-08 味の素株式会社 Conjugate of antibody and functional substance or salt of said conjugate, and compound for use in production of said conjugate or salt of said compound
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CA3129419C (en) * 2021-07-19 2023-02-28 Mabplex International Co., Ltd. Antibody drug conjugate loaded with binary toxins and its application
CN113698468B (en) * 2021-09-01 2022-10-11 浙江新码生物医药有限公司 Human interleukin 2-polyethylene glycol conjugate and application thereof
JPWO2023033129A1 (en) 2021-09-03 2023-03-09
IL311452A (en) 2021-09-16 2024-05-01 Avidity Biosciences Inc Compositions and methods of treating facioscapulohumeral muscular dystrophy
CA3237379A1 (en) 2021-11-09 2023-05-19 Marc-Andre Kasper Conjugates comprising a phosphorus (v) and a camptothecin moiety
EP4429708A1 (en) 2021-11-09 2024-09-18 Tubulis GmbH Conjugates comprising a phosphorus (v) and a drug moiety
EP4433096A1 (en) 2021-11-19 2024-09-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
AU2022422149A1 (en) 2021-12-23 2024-08-01 Mirecule, Inc. Compositions for delivery of polynucleotides
WO2023139608A1 (en) * 2022-01-23 2023-07-27 Celagenex Research (India) Pvt. Ltd. Synergistic Compositions For Enhancing TFEB-Mediated Intracellular Clearance
KR20230127918A (en) * 2022-02-25 2023-09-01 앱티스 주식회사 Novel antibody drug conjugate
IL315508A (en) 2022-03-17 2024-11-01 Seagen Inc Camptothecin conjugates
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
IL316062A (en) 2022-04-14 2024-11-01 Debiopharm Res & Manufacturing S A Ligand-drug-conjugates with improved pharmacokinetic and drug release properties
WO2023215740A1 (en) 2022-05-06 2023-11-09 Seagen Inc. Immunomodulatory antibody-drug conjugates
WO2023223097A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody drug conjugates
WO2023227660A1 (en) 2022-05-25 2023-11-30 Innate Pharma Nectin-4 binding agents
WO2023239803A1 (en) * 2022-06-08 2023-12-14 Angiex, Inc. Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
CN117281900A (en) * 2022-06-16 2023-12-26 亚飞（上海）生物医药科技有限公司 Conjugate of tumor microenvironment activated anti-CTLA-4 antibody and application thereof
WO2023250339A2 (en) * 2022-06-21 2023-12-28 Washington University Vla4 inhibitors and uses thereof
WO2024020164A2 (en) 2022-07-21 2024-01-25 Firefly Bio, Inc. Glucocorticoid receptor agonists and conjugates thereof
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024030577A1 (en) 2022-08-03 2024-02-08 Seagen Inc. Immunostimulatory anti-pd-l1-drug conjugates
EP4321522A1 (en) 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof
WO2024049931A1 (en) 2022-09-02 2024-03-07 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
TW202421120A (en) 2022-09-09 2024-06-01 英商邁瑞科艾克斯醫藥有限公司 Novel compounds and their use in therapy
US20240139289A1 (en) * 2022-09-30 2024-05-02 Extend Biosciences, Inc. Long-acting parathyroid hormone
WO2024089013A1 (en) 2022-10-25 2024-05-02 Peptomyc, S.L. Combination therapy for the treatment of cancer
WO2024091437A1 (en) 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
WO2024096564A1 (en) * 2022-11-01 2024-05-10 앱티스 주식회사 Antibody-drug conjugate comprising anti-claudin-18.2 antibody, and therapeutic use thereof for cancer
WO2024107765A2 (en) 2022-11-14 2024-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
US20240226313A1 (en) 2022-11-17 2024-07-11 Sanofi Ceacam5 antibody-drug conjugates and methods of use thereof
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
WO2024217923A1 (en) * 2023-04-18 2024-10-24 Astrazeneca Ab Conjugates comprising cleavable linkers
WO2024220889A1 (en) 2023-04-20 2024-10-24 Seagen Inc. Sting agonist compounds and conjugates thereof

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
DE3689123T2 (en) 1985-11-01 1994-03-03 Xoma Corp MODULAR UNIT OF ANTIBODY GENES, ANTIBODIES MADE THEREOF AND USE.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5851527A (en) 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
DE68925966T2 (en) 1988-12-22 1996-08-29 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6569834B1 (en) 1992-12-03 2003-05-27 George R. Pettit Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JP3469580B2 (en) 1993-10-01 2003-11-25 帝国臓器製薬株式会社 New peptide derivatives
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
JP2763020B2 (en) 1995-04-27 1998-06-11 日本電気株式会社 Semiconductor package and semiconductor device
US5756593A (en) 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
ATE234635T1 (en) 1995-12-22 2003-04-15 Bristol Myers Squibb Co COUPLERS CONTAINING BRANCHED HYDRAZONE GROUPS
ATE279947T1 (en) 1996-03-18 2004-11-15 Univ Texas IMMUNOGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-LIFE TIMES
US7011812B1 (en) 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
CA2253904A1 (en) 1996-05-03 1997-11-13 Immunomedics, Inc. Targeted combination immunotherapy of cancer
IL128229A0 (en) 1996-08-02 1999-11-30 Ortho Mcneil Pharm Inc Polypeptides having a single covalently bound n-terminal water-soluble polymer
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US20040009166A1 (en) 1997-04-30 2004-01-15 Filpula David R. Single chain antigen-binding polypeptides for polymer conjugation
AU7266698A (en) 1997-04-30 1998-11-24 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
GB2332539B (en) 1997-12-17 2003-04-23 Fujitsu Ltd Memory access methods and devices for use with random access memories
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US7060479B2 (en) 1999-12-08 2006-06-13 Serono Genetics Institute, S.A. Full-length human cDNAs encoding potentially secreted proteins
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6214330B1 (en) 1998-07-13 2001-04-10 Enzon, Inc. Coumarin and related aromatic-based polymeric prodrugs
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
JP2000230000A (en) * 1999-02-08 2000-08-22 Hokkaido Univ Nitrogen monoxide metabolite-polyoxyalkylene- hemoglobin conjugate combination
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
US6777387B2 (en) 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
AU2001272017A1 (en) 2000-06-20 2002-01-02 Immunomedics Inc. Targeted combination immunotherapy of cancer and infectious diseases
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
JP4179771B2 (en) 2001-06-25 2008-11-12 株式会社デンソー Car occupant protection device
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US7026440B2 (en) 2001-11-07 2006-04-11 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
EP1585817B1 (en) 2002-02-20 2009-09-02 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
GB0218518D0 (en) 2002-03-22 2002-09-18 Aventis Pharma Inc Human deubiquitinating protease gene on chromosome 7 and its murine ortholog
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
EP1545613B9 (en) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US7413738B2 (en) 2002-08-13 2008-08-19 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on biodegradable linkers
WO2004044223A2 (en) 2002-11-12 2004-05-27 Enzon Pharmaceuticals, Inc. Prodrugs of vancomycin with hydrolysis resistant polymer linkers
AU2003287605A1 (en) 2002-11-12 2004-06-03 Enzon Pharmaceuticals, Inc. Polymeric prodrugs of vancomycin
DE10254439A1 (en) 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysins, manufacturing processes and tubulysin agents
US7888536B2 (en) 2004-02-13 2011-02-15 Quanta Biodesign, Ltd. Selective and specific preparation of discrete PEG compounds
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
SG170618A1 (en) 2003-04-13 2011-05-30 Enzon Pharmaceuticals Inc Polymeric oligonucleotide prodrugs
MX342007B (en) 2003-05-14 2016-09-09 Immunogen Inc Drug conjugate composition.
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
ES2605443T3 (en) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2005099768A2 (en) 2004-03-23 2005-10-27 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
AU2005244980B2 (en) 2004-05-19 2011-09-15 E. R. Squibb & Sons, L.L.C. Chemical linkers and conjugates thereof
US8288352B2 (en) 2004-11-12 2012-10-16 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
US20070134243A1 (en) 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
EP1844076A2 (en) 2005-01-31 2007-10-17 Genentech, Inc. Anti-ephb2 antibodies and methods using same
JP4877225B2 (en) 2005-02-18 2012-02-15 日油株式会社 Polyoxyalkylene derivatives
JP5122441B2 (en) 2005-04-19 2013-01-16 シアトル ジェネティックス， インコーポレイテッド Humanized anti-CD70 binding agents and uses thereof
US8132476B2 (en) 2005-06-20 2012-03-13 Hy-Energy, Llc Method and apparatus for handling small quantities of fluids
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
CA2616005C (en) 2005-07-18 2015-09-22 Seattle Genetics, Inc. Beta-glucuronide-linker drug conjugates
US20110014151A1 (en) 2006-01-11 2011-01-20 Biotech Igg Ab Macromolecule conjugate
PL1813614T3 (en) 2006-01-25 2012-03-30 Sanofi Sa Cytotoxic agents comprising new tomaymycin derivatives
US7750116B1 (en) * 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
WO2008025020A2 (en) 2006-08-25 2008-02-28 Seattle Genetics, Inc. Cd30 binding agents and uses thereof
MX2009002855A (en) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Targeted polymeric prodrugs containing multifunctional linkers.
US8367065B2 (en) 2006-09-15 2013-02-05 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
BRPI0716808A2 (en) 2006-09-15 2013-11-05 Enzon Pharmaceuticals Inc Lysine-Based Polymeric Binders
WO2008034123A2 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
EP2089425B1 (en) * 2006-11-10 2011-08-17 CovX Technologies Ireland Limited Anti-angiogenic compounds
WO2008070593A2 (en) * 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
US7884869B2 (en) 2007-04-30 2011-02-08 Motorola Mobility, Inc. Assignment of pixel element exposure times in digital camera modules and mobile communication devices
CN101784565B (en) 2007-06-25 2014-12-10 恩多塞特公司 Conjugates containing hydrophilic spacer linkers
TW200922624A (en) 2007-07-11 2009-06-01 Enzon Pharmaceuticals Inc Polymeric drug delivery system containing a multi-substituted aromatic moiety
TW200922623A (en) 2007-07-11 2009-06-01 Enzon Pharmaceuticals Inc Polymeric drug delivery systems containing an aromatic allylic acid
EP2181101A2 (en) 2007-07-20 2010-05-05 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysin d analogues
BRPI0721948A2 (en) 2007-08-20 2014-04-08 Enzon Pharmaceuticals Inc POLYMERIC LEADERS CONTAINING FRACTIONS PYRIDYL DISULFECTURE
AU2008311815B2 (en) 2007-10-19 2014-02-06 Seagen Inc. CD19 binding agents and uses thereof
DK2842575T3 (en) 2008-03-18 2017-11-27 Seattle Genetics Inc Auristatin drug linker conjugates
EP2174947A1 (en) 2008-09-25 2010-04-14 Universität des Saarlandes Bioactive pre-tubulysins and use thereof
CN102215688A (en) 2008-10-21 2011-10-12 安龙制药公司 Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
WO2010081004A1 (en) 2009-01-09 2010-07-15 Seattle Genetics, Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
CA2750519C (en) 2009-02-05 2018-09-25 Immunogen, Inc. Benzodiazepine derivatives
FR2949469A1 (en) 2009-08-25 2011-03-04 Sanofi Aventis ANTICANCER DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
US20110070248A1 (en) 2009-09-24 2011-03-24 Seattle Genetics, Inc. Dr5 ligand drug conjugates
EP2486023A4 (en) 2009-10-06 2014-05-07 Immunogen Inc Potent conjugates and hydrophilic linkers
US8785371B2 (en) 2009-12-10 2014-07-22 Cedars-Sinai Medical Center Drug delivery of temozolomide for systemic based treatment of cancer
MX2012008884A (en) 2010-02-08 2012-08-31 Agensys Inc Antibody drug conjugates (adc) that bind to 161p2f10b proteins.
US9725500B2 (en) 2010-03-02 2017-08-08 Seattle Genetics, Inc. Methods for screening antibodies
JP2013528665A (en) 2010-03-26 2013-07-11 メルサナ セラピューティックス， インコーポレイテッド Modified polymers for delivery of polynucleotides, methods for their production, and methods of their use
MX368648B (en) 2010-04-15 2019-10-09 Seattle Genetics Inc Pyrrolobenzodiazepines used to treat proliferative diseases.
CN102933236B (en) 2010-04-15 2014-10-08 斯皮罗根有限公司 Pyrrolobenzodiazepines and conjugates thereof
CN103068405A (en) 2010-04-15 2013-04-24 西雅图基因公司 Targeted pyrrolobenzodiazapine conjugates
CN102869254A (en) 2010-04-16 2013-01-09 安龙制药公司 Polymeric conjugates of adenine nucleoside analogs
EP2409983A1 (en) 2010-07-19 2012-01-25 Leibniz-Institut für Pflanzenbiochemie (IPB) Tubulysin analogues
PL3156420T3 (en) 2010-12-06 2019-08-30 Seattle Genetics, Inc. Humanized antibodies to liv-1 and use of same to treat cancer
CN113896731A (en) 2011-02-15 2022-01-07 伊缪诺金公司 Cytotoxic benzodiazepine derivatives
PL2678037T3 (en) * 2011-02-25 2015-05-29 Lonza Ag Branched linker for protein drug conjugates
CA2837586C (en) 2011-05-27 2018-12-11 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
WO2013033476A1 (en) 2011-08-30 2013-03-07 Quanta Biodesign, Ltd. Branched discrette peg constructs
SG11201400770SA (en) 2011-09-20 2014-04-28 Spirogen Sarl Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates
CN108164551A (en) 2011-10-14 2018-06-15 西雅图基因公司 Pyrrolobenzodiazepines Zhuo and targeting conjugate
BR112014009055B1 (en) 2011-10-14 2021-12-14 Seattle Genetics, Inc. PYRROLOBENZODIAZEPINE COMPOUNDS, TARGET CONJUGATES, DRUG BINDING AND USE OF SAID CONJUGATES TO TREAT A PROLIFERATIVE DISEASE
US9399073B2 (en) 2011-10-14 2016-07-26 Seattle Genetics, Inc. Pyrrolobenzodiazepines
US9493566B2 (en) 2012-02-17 2016-11-15 Seattle Genetics, Inc. Antibodies to integrin AVB6 and use of same to treat cancer
US20130225789A1 (en) 2012-02-29 2013-08-29 Yi Sun Polyethylene Glycol Having Hetero Multiple Functional Groups
JP6290187B2 (en) 2012-05-11 2018-03-07 クランツ，アレクサンダー Site-specific labeling and targeted delivery of proteins for the treatment of cancer
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
US9981046B2 (en) 2012-05-15 2018-05-29 Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. Drug-conjugates, conjugation methods, and uses thereof
AU2013263002C1 (en) * 2012-05-15 2018-05-31 Seagen Inc. Self-stabilizing linker conjugates
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
US9650331B2 (en) 2012-06-18 2017-05-16 Polytherics Limited Conjugation reagents
ES2782248T3 (en) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Antibody-drug conjugate produced by binding through a linker having a hydrophilic structure
BR112015008376A2 (en) 2012-10-24 2017-09-26 Polytherics Ltd drug-protein conjugates
SG10201806917PA (en) 2013-10-15 2018-09-27 Seattle Genetics Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof

Also Published As

Publication number Publication date
HUE051389T2 (en) 2021-03-01
KR20220018616A (en) 2022-02-15
KR20230082060A (en) 2023-06-08
WO2015057699A2 (en) 2015-04-23
AU2020202853B2 (en) 2022-04-07
IL275830A (en) 2020-08-31
BR112016007622A2 (en) 2018-01-23
CN105764503A (en) 2016-07-13
TWI681778B (en) 2020-01-11
JP2022043354A (en) 2022-03-15
NZ758050A (en) 2024-03-22
CA3187392A1 (en) 2015-04-23
DK3057585T3 (en) 2020-10-19
KR102645430B1 (en) 2024-03-11
WO2015057699A3 (en) 2015-09-24
TW202417050A (en) 2024-05-01
JP2023116821A (en) 2023-08-22
MX2021008463A (en) 2021-08-19
MX2016004609A (en) 2016-08-01
IL293071A (en) 2022-07-01
US20240325561A1 (en) 2024-10-03
EP3057585A2 (en) 2016-08-24
KR102538993B1 (en) 2023-06-02
IL278198B (en) 2022-03-01
SI3057585T1 (en) 2020-12-31
KR20240034882A (en) 2024-03-14
AU2014337555C1 (en) 2021-01-28
MX2021008464A (en) 2023-03-03
JP2016534990A (en) 2016-11-10
AU2020202853A1 (en) 2020-05-21
KR20160062137A (en) 2016-06-01
EP3057585A4 (en) 2017-09-13
JP7330309B2 (en) 2023-08-21
ZA201601436B (en) 2020-07-29
SG11201600954XA (en) 2016-03-30
JP6747971B2 (en) 2020-08-26
CY1123675T1 (en) 2021-05-05
TWI811726B (en) 2023-08-11
EP3057585B1 (en) 2020-07-22
JP2020012002A (en) 2020-01-23
TWI736047B (en) 2021-08-11
CA2921707A1 (en) 2015-04-23
IL244034A0 (en) 2016-04-21
AU2014337555A1 (en) 2016-03-03
EP3756663A1 (en) 2020-12-30
NZ758047A (en) 2024-03-22
PT3057585T (en) 2020-10-21
KR102356814B1 (en) 2022-01-28
US11103593B2 (en) 2021-08-31
US20220072146A1 (en) 2022-03-10
IL275830B (en) 2022-06-01
AU2022204701A1 (en) 2022-07-21
PL3057585T3 (en) 2020-12-28
IL278198A (en) 2020-11-30
NZ717668A (en) 2024-03-22
US20160310612A1 (en) 2016-10-27
TW202214300A (en) 2022-04-16
AU2014337555B2 (en) 2020-05-21
SG10201707274WA (en) 2017-10-30
NZ758049A (en) 2024-03-22
TW202010517A (en) 2020-03-16
TW201515662A (en) 2015-05-01
CA2921707C (en) 2023-03-28
MX2021008465A (en) 2021-08-19
ES2826398T3 (en) 2021-05-18
EA201690780A1 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
SG10201806917PA (en) Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
ZA202004099B (en) Methylene carbamate linkers for use with targeted-drug conjugates
IN2014MN01724A (en)
MY189483A (en) Purinone derivative
CL2015000829A1 (en) Histone Demethylase Inhibitors
PH12015501422A1 (en) Hydrophilic self-immolative linkers and conjugates thereof
WO2011113030A3 (en) Human cancer micro-rna expression profiles predictive of chemo-response
UY31543A1 (en) SYSTEM OF ADMINISTRATION OF RNAI OF INTERFERENCE AND USES OF THE SAME
BR112014032990A2 (en) syringe
MY156938A (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
BR112014019990A8 (en) ENEDIINE COMPOUNDS, THEIR CONJUGATES AND USES AND METHODS FOR THESE COMPOUNDS
EP2853543A8 (en) Anti-blys antibody
MA33939B1 (en) 5-alkynyl-PYRIMIDINE
MX2011010930A (en) Modulation of inflammatory responses by factor xi.
BR112013029158A2 (en) lixisenatide as an add-on therapy for basal insulin and type 2 diabetes
PH12015501088A1 (en) Dimeric compounds
EA201491702A1 (en) OPTIMIZED THERAPEUTIC AGENTS FOR SCRAPTURE INTRODUCTION
CL2013002823A1 (en) Compounds derived from morpholinothieno [3,2-d] pyrimidin-6-yl-methyl- (methylamino) -n-hydroxypyrimidine-5-carboxamide, inhibitors of pi3 kinase; pharmaceutical composition that includes them; its use in the treatment of a cell proliferation disorder such as cancer.
PH12015501115B1 (en) Learning and memory improver
MX2014008373A (en) Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3.
PH12018501351A1 (en) Cortistatin analogs and uses thereof
CL2013001445A1 (en) Compounds derived from diphenylamine; Pharmaceutical composition and use in the treatment of inflammatory diseases, such as cancer.
WO2014093818A3 (en) Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
MX2014008590A (en) Integrin antagonist conjugates for targeted delivery to cells expressing lfa-1.
Wenping et al. People-to-People Cooperation: Foundation to Consolidate China-Africa Relationsr